US FDA accepts Optinose’s sNDA for chronic rhinosinusitis therapy Xhance
Pharmaceutical Technology
MAY 5, 2023
The US Food and Drug Administration (FDA) has accepted Optinose’s supplemental new drug application (sNDA) for Xhance (fluticasone propionate) to treat chronic rhinosinusitis, which is now under review. The regulator has set 16 December 2023 as a prescription drug user fee act (PDUFA) target goal date.
Let's personalize your content